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Proteolytic Activation Cascade of the Netherton
Syndrome–Defective Protein, LEKTI, in the
Epidermis: Implications for Skin Homeostasis
Paola Fortugno1, Alberto Bresciani2, Chantal Paolini3, Chiara Pazzagli1, May El Hachem4,
Marina D’Alessio1,5 and Giovanna Zambruno1,5
Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is the defective protein of the ichthyosiform condition
Netherton syndrome (NS). Strongly expressed in the most differentiated epidermal layers, LEKTI is a serine
protease inhibitor synthesized as three different high-molecular-weight precursors, which are rapidly
processed into shorter fragments and secreted extracellularly. LEKTI polypeptides interact with several
proteases to regulate skin barrier homeostasis as well as inflammatory and/or immunoallergic responses. Here,
by combining antibody mapping, N-terminal sequencing, and site-specific mutagenesis, we defined the amino-
acid sequence of most of the LEKTI polypeptides physiologically generated in human epidermis. We also
identified three processing intermediates not described so far. Hence, a proteolytic cascade model for LEKTI
activation is proposed. We then pinpointed the most effective fragments against the desquamation-related
kallikreins (KLKs) and we proved that LEKTI is involved in stratum corneum shedding as some of its
polypeptides inhibit the KLK-mediated proteolysis of desmoglein-1. Finally, we quantified the individual LEKTI
fragments in the uppermost epidermis, showing that the ratios between LEKTI polypeptides and active KLK5 are
compatible with a fine-tuned inhibition. These findings are relevant both to the understanding of skin
homeostasis regulation and to the design of novel therapeutic strategies for NS.
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INTRODUCTION
Serine proteases and their specific inhibitors have recently
been shown to have a pivotal role in maintaining a perfect
balance between epidermal cell proliferation and desquama-
tion. Alterations of this equilibrium lead to defective
epidermal differentiation and barrier function, as attested by
inherited diseases such as Netherton syndrome (NS, OMIM
266500) and autosomal recessive ichthyosis with hypotri-
chosis (OMIM 610765), and by several animal models
(Ovaere et al., 2009). In particular, NS is caused by lack of
expression of the lympho-epithelial Kazal-type-related
inhibitor (LEKTI) and is characterized by congenital erythro-
dermic ichthyosis, hair defects, and atopic manifestations
(Comel, 1949; Netherton, 1958; Chavanas et al., 2000).
Severe complications, such as recurrent bacterial infections,
hypernatremic dehydratation, and failure to thrive, frequently
compromise NS prognosis in infants.
LEKTI is a serine protease inhibitor whose primary
structure recalls that of the Kazal-type family. However,
unlike its related molecules, LEKTI shows as many as 15
inhibitory domains (D1–D15) (Magert et al., 1999). LEKTI D2
and D15 contain a typical Kazal motif with the canonical six
cysteine residues, whereas the remaining 13 domains present
a Kazal-related structure that misses one of the three
conserved disulfide bridges. However, all LEKTI domains
are still able to generate the typical Kazal-binding loop
hairpin structure (Lauber et al., 2003). In human, alternative
pre-mRNA processing generates three LEKTI isoforms differ-
ing only in their C-terminal portion: LEKTI full-length with 15
domains (LEKTIFL, 145-kDa), a long isoform (LEKTIL,
148 kDa) carrying a 30 amino-acid residue insertion between
D13 and D14, and a short isoform (LEKTISh, 125 kDa)
composed of the first 13 domains (Tartaglia-Polcini et al.,
2006). All LEKTI isoforms contain a signal peptide and the
inhibitory domains are separated by linker regions that can be
cleaved by subtilisin-like proprotein convertases, such as
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On the basis of in vitro and in vivo evidences, the
following model for LEKTI functioning in the epidermis has
been proposed: LEKTI is at first synthesized as precursor
proteins by differentiating keratinocytes of the upper spinous/
granular layers, and then cleaved by furin to generate several
single or multi-domain polypeptides in a post-endoplasmic
reticulum compartment (Bitoun et al., 2003; Tartaglia-Polcini
et al., 2006). Thereafter, these fragments are transported
by specific intracellular lamellar granule cargoes to the
extracellular space between granular and horny layers
(Ishida-Yamamoto et al., 2005); there they prevent premature
corneodesmosome degradation by forming inhibitory com-
plexes with serine proteases involved in epidermal desqua-
mation, such as kallikreins (KLKs) (Borgono et al., 2007;
Deraison et al., 2007). Finally, progressive stratum corneum
(SC) acidification mediates the release of active KLKs from
LEKTI fragments (Deraison et al., 2007), allowing degradation
of corneodesmosomal components and the physiological
exfoliation of the SC outermost layers. Accordingly, LEKTI
deficiency results, both in human and mouse, in increased
serine protease activity at the granular and transitional cell
layers, premature corneodesmosome cleavage, and loss of
skin barrier function. Nevertheless, the analysis of LEKTI-
deficient skin showed several additional alterations such as
abnormal profilaggrin processing, SC lipid disorganization,
and overexpression of proinflammatory and proallergic
molecules (Yang et al., 2004; Descargues et al., 2005,
2006; Hewett et al., 2005). These data allowed the
recognition of the involvement of LEKTI in other biological
pathways (Bonnart et al., 2010; Briot et al., 2010). In light of
the LEKTI multi-functional role and its peculiar primary
structure, it can be hypothesized that both transcriptional and
post-transcriptional modifications contribute to the genera-
tion of an ample number of fragments with related but distinct
structure and role. Consistently, several in vitro studies have
shown that each single or multi-domain LEKTI fragment
displays a specific inhibitory profile toward epidermal
proteases (Borgono et al., 2007; Deraison et al., 2007).
However, most of the polypeptides tested represented
‘‘putative’’ bioactive fragments. In fact, although the activa-
tion of LEKTI precursors by furin has been demonstrated by
different groups, thus so far, only few physiological fragments
have been identified.
In this study, by combining antibody (Ab) mapping,
N-terminal sequencing, and site-specific mutagenesis, we
defined the amino-acid sequence of most of the LEKTI
polypeptides physiologically generated in human keratino-
cytes (HKs). We also showed that some of these fragments are
powerful inhibitors of KLK5 and 14, and are able to prevent
KLK-mediated proteolysis of desmoglein-1 (DSG1). Finally,
we demonstrated that, in the epidermal granular/horny
layers, the relative amounts of LEKTI fragments and active
KLK5 are compatible with a fine-tuned inhibition. All
together, our findings increase the molecular understanding
of LEKTI function and provide the basis for previously
unreported therapeutic interventions for NS and, likely, other
skin disorders presenting deregulated KLKs activity and skin
barrier defects.
RESULTS
Several LEKTI fragments are generated in epidermis, cultured
keratinocytes, and transfected HEK293 cells
To define LEKTI physiological proteolysis, Ab mapping was at
first performed using a newly generated anti-D7D12 poly-
clonal Ab in combination with previously described ones
(Figure 1a). According to previous data (Deraison et al.,
2007), LEKTI precursors could be detected only in the
intracellular fraction of differentiated normal HKs (NHKs)
(not shown), while several LEKTI fragments (65, 68, 42, 37,
30, and 23 kDa) were visualized both in human epidermis
and conditioned medium (CM) of differentiated NHK (Figure
1b). The same signals were also detected in the HEK293
epithelial cell line ectopically expressing C-terminal-tagged
LEKTI proteins, indicating that the proproteins follow the
same processing in both cell types (Figure 1b). Absence of
signals in cells which do not express LEKTI, as proliferating
NHK, NS keratinocytes and HEK 293 transfected with the
empty vector, confirmed Ab specificity (Figure 1b and c). The
molecular weight of the detected bands also excluded cross-
reactivity with the recently discovered single-domain serine
protease inhibitors SPINK6 (B6-kDa) and LEKTI-2 (7.7 and
15 kDa as monomer and dimer, respectively) (Brattsand et al.,
2009; Meyer-Hoffert et al., 2009, 2010). In our experimental
conditions, LEKTI single domains (B7 kDa) could be detected
exclusively by the mAb 1C11G6 in the HEK293 over-
expressing the recombinant protein (Figure 1c). Interestingly,
three additional previously undescribed fragments of 102,
105, or 79 kDa were detected in CM of cells ectopically
expressing LEKTIFL, LEKTIL, and LEKTISh, respectively,
(Figure 1c). As they were also recognized by antibodies
directed to the C-terminal histidine-tag (Figure 1c), it was
inferred that each of them represents a processing inter-
mediate that includes the respective isoform-specific
C-terminal domain. Likely, in human epidermis and NHK,
these fragments are rapidly cleaved to generate the more
stable C-terminal fragments of 65, 68, and 42 kDa (Figure 1b
and c) (Bitoun et al., 2003). As to the 37, 30, and 23-kDa
fragments, they were visualized using the anti-D7D12
and 1C11G6, but not the C-terminal-directed antibodies
(Figure 1b and c), indicating that they do not comprise this
portion of the protein.
LEKTI fragments are generated by cleavage at furin consensus
sequences
In silico analysis of LEKTI primary structure (Swiss-Prot
Q9NQ38) (Duckert et al., 2004) revealed three potential
furin consensus sequences with a significant score (Arg355,
Arg425, and Arg625), as well as several others with lower
values, all located in the linker regions between the inhibitory
domains (Figure 2a). To identify the physiological cleavage
sites, two different strategies were used: N-terminal sequen-
cing of purified polypeptides and mutagenesis of the
predicted positions. In particular, as immunoblotting analysis
indicated that the isoform-specific C-terminal fragments of
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65, 68, and 42 kDa are generated by the usage of the same
cleavage site (Figure 1c), the 42-kDa polypeptide was chosen
as prototype. It was purified from CM of HEK293 expressing
pLEKTISh, and subjected to N-terminal sequencing, which
revealed a perfect match with residues 626–634 of LEKTI
(Figure 2b). This result demonstrated that the 42-kDa
C-terminal fragment originates from the usage of the
Arg625 furin cleavage site located in the linker region
between D9 and D10. To confirm our assumption that the
65 and 68-kDa C-terminal fragments are also generated
by cleavage at Arg625 of the LEKTI longer isoforms, this
residue was mutagenized in the LEKTIFL sequence and the
mutated protein (R625A) was ectopically expressed in the
LEKTI-deficient cells NS keratinocytes and HEK293. Immu-
noblotting of CM from both transfected cell types showed that
processing of the mutated protein does not generate the
65-kDa polypeptide and results in accumulation of the
intermediate C-terminal fragment of 102-kDa (Figure 2c).
Noteworthy, the presence of this fragment in CM of pLEKTIFL-
transfected NS keratinocytes (Figure 2c) demonstrates that
also in HKs, LEKTI cleavage proceeds through the generation
of intermediate products. These findings allowed to conclude
that in HKs, all three LEKTI isoforms are cleaved at Arg625,
thus, generating the C-terminal fragments of 65, 68, and 42kDa,
corresponding to D10-D15FL, D10D15L, and D10D13Sh,
respectively. Furthermore, in R625A LEKTIFL-expressing cells
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Figure 1. LEKTI proteolytic fragments in the epidermis, human keratinocytes, and transfected HEK293. (a) Schematic representation of lympho-epithelial
Kazal-type-related inhibitor (LEKTI) isoforms with location of the antigenic polypeptides used to generate the indicated antibodies. (b) Immunoblotting detection
of LEKTI in: conditioned medium (CM) of HEK293 transfected with pLEKTIFL (1) or empty vector (2), total extract from human epidermis of two healthy donors
(3, 4), CM of proliferating natural human keratinocytes (NHKs) (5), CM of differentiated NHK (6), and Netherton syndrome (NS) keratinocytes (7). Note that the
experimental conditions used did not allow separation of the 65- and 68-kDa fragments, and that the band corresponding to the 65-kDa fragment displays a
higher molecular weight in HEK293 expressing LEKTIFL because of the C-terminal tag. Ponceau S staining was used to ensure even protein loading among similar
samples (lower panel). Different exposures of the same blot (lanes 1–2, 3–4, 5–7) were juxtaposed. (c) Immunoblotting detection of LEKTI in CM of HEK293
transfected with pLEKTIFL, pLEKTIL, or pLEKTISh using the antibodies 1C11G6 (1), anti-D7D12 (2), anti-D13D15 (3), anti-D14D15 (4), or anti-His6 (5). Lower
panels: 1C11G6 and anti-D7D12 immunoblot longer exposures revealing the 23- and 7-kDa fragments. Sizes of immunoreactive bands are indicated.
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also the generation of the newly characterized 37, 30, and
23-kDa fragments was compromised, indicating that the usage
of the Arg625 cleavage site produces either the N- or the
C-terminal end of these polypeptides (Figure 2c).
To verify whether the other predicted furin cleavage sites
are actually used for LEKTI processing, the Arg355, Arg425,
and Arg489 residues were mutagenized in the LEKTIFL
sequence. Although predicted with a low score, the Arg489
was included in the study as a LEKTI fragment starting from
residue Glu490 had been previously described (Ahmed et al.,
2001). Expression of mutant LEKTIFL proteins in HEK293
showed that all the potential furin cleavage sites analyzed are
indeed used for LEKTI processing (Figure 2d). Specifically,
substitution of Arg355 with A (R355A) resulted in loss of both
the 102 and 37-kDa fragments. Mutagenesis of Arg425
(R425A) affected only the 30-kDa polypeptide. Finally, the
substitution R489A resulted in loss of the 23-kDa fragment
(Figure 2d). In some instances, additional bands were
observed, suggesting that impairment of the physiological
cleavage sites prompts usage of alternative sequences
(Figure 2d). Analogous results were obtained expressing the
mutants in NS keratinocytes (not shown). These findings, in
combination with those obtained using the R625A mutant,
allowed to conclude that the 102, 37, 30, and 23-kDa
proteins correspond to D6D15FL, D6D9, D7D9, and D8D9,
respectively.
LEKTI fragments inhibit epidermal proteases
The capability of the newly identified LEKTI polypeptides to
function in vitro as serine protease inhibitors was assessed
against KLK5, KLK7, and KLK14, as they were previously
suggested to represent LEKTI targets being involved in skin
desquamation, cleavage of profilaggrin, and, more in general,
epidermal barrier maintenance, all processes altered in NS
(Brattsand and Egelrud, 1999). Information on the recombi-
nant LEKTI fragments used throughout the present study is
reported in the Supplementary Table S1 and S2 online. The
inhibitory profiles and inhibition constants (Ki) of the LEKTI
fragments that displayed a strong dose-dependent inhibitory
activity are shown in Figure 3. KLK5 and KLK14, which are
the major contributors to the trypsin-like activity in SC, were
indeed inhibited to various extents by the different fragments.
In particular, the strongest inhibitory activity toward KLK14
was observed with D7D9 (Ki¼ 0.16 nM) and toward KLK5
with D8D9 (Ki¼ 5.38 nM) (Figure 3a). In general, fragments
generated from the LEKTI region comprised between D6 and
D9 resulted to be more effective compared with the C-
terminal polypeptides, that, under the specific in vitro assay
conditions, inhibited at most 77% of KLK14 (Vi/V040.33
at [D10D15FL]¼ 12 nM) or 55% of the KLK5 activity
(Vi/V040.45 at [D10D15L]¼ 25 nM) (not shown). In addition,
the single domains D6 and D7 were weaker inhibitors as
compared with the corresponding multi-domain fragments
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Figure 2. Mapping of LEKTI proteolytic fragments. (a) Graphic illustration of predicted proprotein convertase cleavage sites in lympho-epithelial Kazal-type-
related inhibitor (LEKTI) protein. (b) Partial N-terminal amino-acid sequence of the 42-kDa fragment isolated from conditioned medium (CM) of pLEKTISh
transfected HEK293 in alignment with the three human LEKTI isoform sequences. (c) Immunoblotting detection of LEKTI fragments in CM from HEK293
or Netherton syndrome (NS) keratinocytes transfected with LEKTIFL, LEKTI R625A mutant, or the empty vector. The asterisk indicates nonspecific signals.
(d) Immunoblotting detection of LEKTI fragments in CM from HEK293 transfected with either wild type or mutant LEKTI. Samples were separated on 12% (upper
panel) or 15% (lower panel) SDS-PAGE. On the left, schematic representation of LEKTI processing as deduced from N-terminal sequencing and mutagenesis
results. Sizes of immunoreactive bands are indicated. Different exposures of the same blot were juxtaposed.
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(i.e., D6D9 and D7D9), and D6 was less effective than D7
(Figure 3a). For what concerns the chymotrypsin-like activity
of KLK7, although to a lesser extent, it was also inhibited by
LEKTI bioactive fragments. In particular the C-terminal
polypeptides D10D15FL and D10D15L presented the stron-
gest inhibitory activity (Figure 3b), with Ki values of 20.26
and 27.39 nM, respectively. Fragments derived from the LEKTI
region D6–D9 instead showed a low inhibitory activity,
regardless of their concentration (not shown). The isoform-
specific fragment D10D13Sh did not inhibit any of the tested
proteases (not shown).
As recombinant LEKTI degradation by KLKs had previously
been reported (Borgono et al., 2007), the stability of the
naturally occurring LEKTI fragments in presence of epidermal
KLKs was evaluated. CM of differentiated NHK was
incubated with the different peptidases and proteolysis of
each LEKTI fragment assessed over time by immunoblotting.
All LEKTI polypeptides were resistant to KLK5-mediated
hydrolysis and slowly degraded by KLK14 (Figure 4a and
b). Conversely, they were rapidly digested by the chymo-
trypsin-like protease KLK7 (Figure 4c). Interestingly, the
42-kDa LEKTISh C-terminal fragment (D10D13Sh) that did
not show any inhibitory activity against KLK7, was not
digested by this enzyme. Of note, in some instances digestion
of fragments resulted in the generation of discrete polypep-
tides (Figure 4b and c).
LEKTI fragments regulate skin barrier homeostasis by inhibiting
DSG1 degradation
The loss of SC adhesion observed in the skin of both NS
patients and mouse models is mainly because of the
proteolytic degradation of DSG1 concurrent with a signifi-
cant increase of trypsin-like activity in the epidermis
(Descargues et al., 2005, 2006). As DSG1 had been reported
to represent a substrate for both KLK5 and KLK14 (Caubet
et al., 2004; Borgono et al., 2007), the ability of the LEKTI
fragments most effective toward these enzymes to inhibit
DSG1 proteolysis was verified in vitro. In our experimental
conditions, KLK5-mediated proteolysis of DSG1 was quite
slow and reached its completion after 24 hours incubation at
37 1C, whereas almost all the protein was degraded after
1-hour incubation with KLK14 (not shown). However, when
the enzymes were preincubated with different LEKTI frag-
ments, various extents of inhibition were observed (Figure 5).
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Figure 3. Dose-dependent inhibition of KLK activity by recombinant LEKTI fragments. (a) Dose–response inhibition curves of GST-D6 (K), GST-D7 (~),
GST-D6D9 (J), GST-D7D9 (m), and GST-D8D9 (&) toward the trypsin-like serine proteases kallikrein (KLK)5 and KLK14. (b) Dose–response inhibition curves
of D10D15FL-His (n), D10D15L-His (’), and D10D15Sh-His (}) toward the chymotrypsin-like KLK7. (a, b) KLKs were preincubated with increasing
concentrations of inhibitors before addition of the specific substrates described in Supplementary Table S3 online. Residual KLK activity is expressed relative to
control with no inhibitors (Vi/V0). Each data point represents means±SD of three independent assays. Ki values are indicated on the right.
aThe single domain
fragment D6 inhibited at most 35% of KLK5 activity (Vi/V040.65 at [D6]¼25 nM) and the relative Ki value could not be determined (ND). bNI, no inhibition.
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In particular, the multi-domain fragments D6D9, D7D9, and
D8D9 resulted to be, in a quite similar manner, very effective
inhibitors of KLK14-mediated DSG1 proteolysis by preserving
over 80% of DSG1 molecules from cleavage. As to the KLK5-
mediated DSG1 cleavage, a significant inhibitory effect
(B80%) was achieved by the addition of D6D9, whereas a
medium to low inhibitory effectiveness, ranging from 60%
(D7) to 20% (D8D9), was observed with the other fragments
(Figure 5).
Concentration of LEKTI fragments in human epidermis is
congruent with KLK5 inhibition
To further investigate the regulative role of LEKTI toward the
epidermal KLKs, the relative amounts of each LEKTI bioactive
polypeptide and of KLK5 in the epidermis were determined.
As several evidences demonstrated colocalization of LEKTI
with epidermal KLKs at the granular/horny layers (Ishida-
Yamamoto et al., 2005), human skin biopsy samples were
mechanically and chemically treated to obtain epidermal
specimens enriched for these highly differentiated layers
(Figure 6a). Individual LEKTI fragments and KLK5 were then
quantitatively measured by western blot analysis of protein
extracts. Defined amounts of the corresponding recombinant
proteins were used to generate reference standard dilution
curves (Figure 6b). The molar concentrations of LEKTI fragments
D6D9, D7D9, and D8D9 turned out to be comparable to that
of the KLK5 active form (Figure 6b), in keeping with a finely
regulated inhibition. LEKTI C-terminal fragments, instead, were
present in 4- to 7-fold molar excess. These data indicate that,
along with their different inhibitory capability, these LEKTI
polypeptides show a diverse stability in vivo.
DISCUSSION
The defective expression of the multi-domain serine protease
inhibitor LEKTI and the consequent unrestrained protease
activity result in the life-threatening syndromic skin disease
NS. No curative therapies are currently available for this
complex disorder. Topical delivery of LEKTI bioactive
fragments represent the most promising therapeutic approach
for NS. With this thought in mind, we have characterized the
LEKTI polypeptides generated in human epidermis. In
particular, by mapping four physiologically utilized cleavage
sites (Arg355, Arg425, Arg489, and Arg625) we portrayed
eight of the LEKTI bioactive polypeptides (D6, D7, D6D9,
D7D9, D8D9, D10D15FL, D10D15L, and D10D13Sh). We
also identified in cells exogenously expressing LEKTI, three
processing intermediates (D6D15FL, D6D15L, and D6D13Sh)
not described so far. Of note, some of the polypeptides
identified in this study partly differ from previously inferred
ones. In particular, our site-specific mutagenesis experiments
demonstrate that the 23-kDa fragment detected in the
epidermis originates from the cleavages at the Arg489 and
Arg625 furin recognition sites and, thus, corresponds to LEKTI
D8D9. This data partially conforms with the earlier description
of a LEKTI fragment with the N-terminal sequence initiating
with residue Glu490 (Ahmed et al., 2001). However, the
authors estimated the molecular weight of this polypeptide as
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2228 Journal of Investigative Dermatology (2011), Volume 131
P Fortugno et al.
LEKTI Proteolytic Cascade in the Epidermis
30 kDa, likely because of the protein separation methodology
used. Afterward this claim rebounded on the deductive
analysis carried out by Deraison et al. (2007), who incorrectly
defined the 30-kDa fragment as D8D11. In addition, here
several evidences concur in demonstrating that the isoform-
specific C-terminal fragments are generated by cleavage at
residue Arg625 within the linker region between D9 and
D10. Conversely, Deraison et al. (2007) proposed cleavage
between D8 and D9. Incomplete deglycosylation might
account for this misinterpretation.
The identification of LEKTI sequential cleavage products
allowed us to draw an activation cascade model, as depicted
in Figure 6c for LEKTIFL. The first cut takes place between D5
and D6, generating the C-terminal intermediate fragment of
102-kDa (D6D15FL). Subsequently, cleavage between D9
and D10 generates both the 37-kDa fragment D6D9 and the
anti-D13D15
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Figure 6. LEKTI fragments in human epidermis. (a) Immunohistochemical analysis for lympho-epithelial Kazal-type-related inhibitor (LETKI) and kallikrein
(KLK)5 in human epidermis (left panels) and epidermal specimens enriched for granular/horny layers (right panels). Bar¼40 mm. (b) Quantitative analysis of
LEKTI fragments and KLK5 in epidermis enriched for granular/horny layers by immunoblotting. Increasing amounts of protein extracts (expressed as microgram
of uppermost epidermis dry weight) are compared with defined amounts of the corresponding recombinant proteins (expressed in ng). Note that the LEKTI
weight values are relative to the sole polypeptides and not to the entire fusion proteins. The tables on the right show the protein content in the epidermis,
measured as ng per mg of uppermost epidermis dry weight. 1The values indicate the mean of three independent experiments±standard deviation. (c) Model of
LEKTI proteolytic activation cascade as deduced from bioactive peptide mapping. Generation of the D1D5 fragment is inferred on the basis of previously
published data.
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isoform-specific 65-kDa polypeptide D10D15FL. Although
the latter fragment is not further proteolyzed, D6D9 is
cleaved at Arg425, within the linker region between D6
and D7, generating the 30-kDa fragment D7D9 and the
previously characterized single-domain D6 (Magert et al.,
1999). Finally, D7D9 cleavage at Arg489 generates the
23-kDa fragment D8D9 and the single-domain D7. As to the
N-terminal region, although the antibodies used did not
visualize any processing product, we assumed that the
previously described 37-kDa fragment starting from Lys23
(Jayakumar et al., 2005) represents the D1D5 polypeptide
generated by this cleavage. Further cleavages of this LEKTI
portion could not be investigated.
Next, we studied the inhibitory specificities/activities of the
identified LEKTI fragments. Specifically, we analyzed the
epidermal serine proteases KLK5, KLK7, and KLK14, as they
represented the best LEKTI target candidates. Indeed, they
colocalize with the inhibitor (Ishida-Yamamoto et al., 2005;
Komatsu et al., 2005b) and are involved in processes
deregulated in LEKTI-deficient epidermis, in particular skin
desquamation and profilaggrin processing (Brattsand and
Egelrud, 1999; Bonnart et al., 2010; Sales et al., 2010). All
KLKs tested were inhibited by LEKTI polypeptides with Ki in
the nanomolar range. In agreement with the major increase of
trypsin versus chymotrypsin-like activity observed in SC of NS
patient (Komatsu et al., 2008), the strongest inhibition was
achieved toward KLK5 and KLK14, in particular by fragments
derived from the LEKTI region D6–D9. The same polypeptides
were also very effective inhibitors of KLK-mediated DSG1
degradation, a key step in corneocyte shedding. These results
are in line with a NS genotype/phenotype correlation study by
Komatsu et al. (2008) that highlights the important role of
LEKTI D6-D12 region in determining NS severity. On the
basis of the assumption that NS patients synthesize truncated
forms of LEKTI, reliant on the location of mutations, the
authors suggested that expression of this portion of the protein
provides for inhibition of trypsin-like activity and consequent
reduction of the NS clinical manifestations correlated to SC
over-desquamation. For what concerns the activity toward
KLK7, the best inhibition was achieved by LEKTI fragments
D10D15FL and D10D15L. Chymotrypsin-like inhibitory
capability has not been previously described for the LEKTI
C-terminal region (Egelrud et al., 2005; Schechter et al., 2005;
Deraison et al., 2007), possibly due to structural differences or
post-translational modifications of the LEKTI fragments used.
Indeed, we expressed the C-terminal fragments in mammalian
cells to ensure their correct glycosylation/functionality.
However, we also observed that LEKTI fragments are rapidly
degraded by KLK7, suggesting that this protease might not be
their main target in vivo. Altogether, our results formally prove
that the long-stated concept that each LEKTI fragment displays
a specific inhibitory profile holds true for the LEKTI polypep-
tides physiologically generated in the epidermis. However,
some differences between our inhibition assay results and
findings by other groups (Borgono et al., 2007; Deraison et al.,
2007) were noticed. Likely, the nature of the recombinant
proteins tested as well as the experimental conditions used
account for these discrepancies.
In summary, by showing that the herein identified
LEKTI fragments exhibit differential specificity/activity, we
demonstrate that each domain contributes to modulate the
interaction with target proteases. We also prove that the
multi-domain polypeptides are not merely processing inter-
mediates on the way to single-domain inhibitors, but
represent the truly active forms. Finally and most importantly,
we demonstrate that the LEKTI polypeptides derived from the
central portion of the proprotein are capable to block the
KLK-mediated DSG1 degradation. Moreover, at the site of
their potential interaction, these LEKTI fragments and KLK5
are present in a nearly 1:1 molar ratio, which is essential for a
fine-tuned inhibition. Of note, the amount of KLK5 measured
in our samples is comparable to that previously calculated by
Komatsu et al. (2005a) in human SC using a different
methodology. This correspondence allows to widen the
considerations about the LEKTI fragments/KLK5 ratio to other
KLKs described in that study.
These findings are relevant to the understanding of skin
homeostasis regulation. In addition, they gain upon the
design of a previously unreported and effective therapeutic
intervention for NS, based on the replacement of the missing
LEKTI polypeptides. The currently utilized therapies for this
life-threatening and disabling disease are only aimed at
reducing the clinical symptoms (Saif and Al-Khenaizan,
2007; Renner et al., 2009). Nevertheless, in spite of the
encouraging results (Di et al., 2010; Roedl et al., 2011), the
ex-vivo gene transfer cannot be envisaged as an imminent
therapeutic option. Local delivery through the horny layer, by
means of topical application or non-invasive mini-gene
transfer (Foldvari et al., 2006) of LEKTI bioactive fragments
could attenuate unopposed KLKs activity and counteract the
skin barrier impairment of NS patients. Although the efficacy
and safety in vivo of the ‘‘putative’’ LEKTI fragments studied
by others cannot be predicted, it is fair to expect for a
beneficial effect by the LEKTI physiological fragments.
Fine-tuning of serine proteases activity could represent
an important pharmacological tool also for more common
skin diseases presenting increased SC serine proteases
activity and altered epidermal barrier function, such as
atopic dermatitis. The analysis of the inhibitory properties
of the herein identified LEKTI fragments toward other
epidermal serine proteases, shown to be involved in the
pathways altered in NS, represents an important area for
future studies.
MATERIALS AND METHODS
Purification of the 42-kDa LEKTI fragment
LEKTISh 42-kDa fragment was purified from the CM of HEK293
transfected with pLEKTISh using Ni-NTA Agarose (Qiagen, Hilden,
Germany). The fragment was processed for N-terminal sequencing
by Primm-srl (Milano, Italy).
Protein extract preparation
The study was conducted according to the Declaration of Helsinki
Principles. Approval from the IDI-IRCCS Ethics Committee and
informed consent from NS patient/healthy donors were obtained for
all described studies that used human materials.
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Cultured cells were lysed in RIPA buffer containing Complete
(Roche Applied Science, Mannheim, Germany). Lysates were
clarified by centrifugation at 13,000 g, 4 1C for 15minutes. The
CM was concentrated by acetone precipitation. Skin biopsy samples
of three healthy volunteers undergoing abdominal plastic surgery
were processed for epidermal protein extracts generation. Following
dermal-epidermal cleavage by heating 5minutes at 56 1C in PBS, the
epidermis was homogenized on ice with Ultra-Turrax in RIPA buffer
with Complete. Epidermal extracts used for DSG1 degradation
assays were prepared as described (Caubet et al., 2004).
LEKTI fragment proteolysis assay
Secreted proteins, concentrated from CM of differentiated NHK by
acetone precipitation, were incubated with 50 ng of proteases up to
24 hours at 37 1C. Samples, boiled for 2minutes in Laemmli buffer,
were separated on 12% SDS-PAGE and immunoblotted.
DSG1 degradation inhibitory assay
Fifty nanogram of KLK5 or KLK14 was pre-incubated for 10minutes
at RT with 4-fold molar excess of recombinant LEKTI fragments
or equivalent buffer volume. The mixture enzyme inhibitor, or
equivalent volume of proteolysis buffer (10mM sodium phosphate
buffer, pH 7.2, 0.15 M NaCl), was added to 70 mg of epidermal
extracts and incubated at 37 1C for 24 hours for KLK5 assays or for
90minutes for KLK14 assays. To evaluate the inhibitory activity of
recombinant LEKTI fragments, the amount of intact DSG1 detected
by immunoblotting was assessed by densitometric analysis. The
inhibition efficacy was given by the ratio between the DSG1
molecules still detected after incubation with both protease and
inhibitors relative to protease-free controls.
Preparation of epidermal specimens enriched for granular/
horny layers
Skin biopsy samples obtained from healthy volunteers were
mechanically and chemically treated following a previously
published protocol (Toulza et al., 2007), with minor modifications.
Procedure details are described in the Supplementary Material
online.
Additional information regarding the antibodies, cell culturing
and DNA transfection, enzyme, substrates and kinetic inhibition
assays is available in the Supplementary Material online.
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